Free tool
Drug Trial Radar: Infectious disease and vaccines
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
502
Completed, industry sponsors, Infectious disease and vaccines, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed502
502 trials
Showing 1 to 25, recently updated first.
GlaxoSmithKlineGSK (GSK)
NCT05305651 · 217 participants · Start Jul 1, 2022 · Primary completion Jul 17, 2023
Drug: Sotrovimab · For: COVID-19
Sites: Birmingham, United Kingdom; Cambridge, United Kingdom; Cardiff, United Kingdom · 8 sites in all
- A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT05514509 · 295 participants · Start Oct 28, 2022 · Primary completion Sep 2, 2025
Drug: APRETUDE; Cabotegravir tablet · For: HIV Infections
Sites: Washington D.C., District of Columbia; Miami, Florida; Orlando, Florida · 22 sites in all
- Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Skin InfectionsPivotal-lookingCompleted
Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
NCT00368537 · 550 participants · Start Sep 2006 · Primary completion Sep 2008
Drug: Tigecycline; ampicillin-sulbactam · For: Skin Diseases, Bacterial
Sites: Scottsdale, Arizona; Jonesboro, Arkansas; Chula Vista, California · 57 sites in all
Kyowa Kirin China Pharmaceutical Co., Ltd.Industry
NCT06285370 · 23 participants · Start May 29, 2023 · Primary completion Aug 12, 2025
Drug: Mogamulizumab · For: Cutaneous T-Cell Lymphoma
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 8 sites in all
CanSino Biologics Inc.Industry
NCT06389513 · 3,011 participants · Start Jun 12, 2024 · Primary completion Apr 10, 2026
Drug: MCV4 · For: Epidemic Meningitis
Sites: Nanjing, China
- Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)Pivotal-lookingCompleted
Dr. Md. Alimur RezaIndustry
NCT06804096 · 129 participants · Start Feb 20, 2025 · Primary completion Jan 12, 2026
Drug: Faropenem; Co-amoxiclav and 1 more · For: Pneumonia, Community-Acquired; Bacterial Pneumonia
Sites: Dhaka, Bangladesh · 2 sites in all
ModernaTX, Inc.Moderna (MRNA)
NCT07089706 · 832 participants · Start Jul 21, 2025 · Primary completion Jun 16, 2026
Drug: mRNA-1283.251 Variant-containing Formulation · For: COVID-19
Sites: Atlanta, Georgia; Baton Rouge, Louisiana; New Orleans, Louisiana · 5 sites in all
NovavaxIndustry
NCT06633835 · 660 participants · Start Sep 19, 2024 · Primary completion Dec 30, 2024
Drug: protein subunit: Novavax COVID-19 vaccine; Pfizer mRNA COVID-19 vaccine · For: COVID-19; Vaccine-Preventable Diseases; SARS CoV 2 Infection
Sites: Salt Lake City, Utah
PfizerPfizer (PFE)
NCT05630976 · 70 participants · Start Feb 7, 2023 · Primary completion Apr 11, 2025
Drug: Isavuconazole · For: Invasive Fungal Disease
Sites: Hefei, China; Guangzhou, China; Jieyang, China · 14 sites in all
- A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United StatesPivotal-lookingCompleted
ViiV HealthcareGSK (GSK)
NCT05374525 · 287 participants · Start May 18, 2022 · Primary completion Aug 8, 2024
Drug: APRETUDE; Cabotegravir OLI · For: HIV Infections
Sites: Los Angeles, California; San Francisco, California; Washington D.C., District of Columbia · 17 sites in all
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04109222 · 90 participants · Start Sep 30, 2019 · Primary completion Dec 10, 2019
Drug: Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation; Fluzone High-Dose vaccine, 2019-2020 formulation · For: Influenza
Sites: Bardstown, Kentucky; Salt Lake City, Utah
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT04551677 · 90 participants · Start Sep 16, 2020 · Primary completion Dec 18, 2020
Drug: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation; Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation · For: Influenza Immunization; Healthy Volunteers
Sites: Bardstown, Kentucky; Salt Lake City, Utah
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05050318 · 90 participants · Start Sep 8, 2021 · Primary completion Nov 10, 2021
Drug: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation; Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation · For: Influenza Immunization; Healthy Volunteers
Sites: Bardstown, Kentucky; Salt Lake City, Utah
Nanogen Pharmaceutical Biotechnology Joint Stock CompanyIndustry
NCT06922643 · 100 participants · Start Mar 1, 2011 · Primary completion Jan 21, 2013
Drug: Peginterferon Alfa-2A; Ribavirin Oral Product · For: Chronic Hepatitis C
- Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)Pivotal-lookingCompleted
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT06987942 · 899 participants · Start Sep 21, 2024 · Primary completion Nov 15, 2024
Drug: Varicella vaccine+TIV; Varicella vaccine and 1 more · For: Varicella; Influenza Vaccine
Sites: Nanjing, China
- Clinical Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Patients With Chronic Hepatitis BPivotal-lookingCompleted
Samjin Pharmaceutical Co., Ltd.Industry
NCT05286346 · 113 participants · Start Oct 12, 2018 · Primary completion Aug 10, 2020
Drug: Tenofovir disoproxil 245mg; Tenofovir disoproxil fumarate 300mg · For: Chronic Hepatitis b
Sites: Busan, South Korea
Novartis PharmaceuticalsNovartis (NVS)
NCT04869358 · 34 participants · Start May 27, 2021 · Primary completion May 10, 2022
Drug: Ofatumumab · For: Relapsing Multiple Sclerosis
Sites: Berlin, Germany; Bielefeld, Germany; Dresden, Germany · 6 sites in all
ViiV HealthcareGSK (GSK)
NCT04982445 · 44 participants · Start Nov 18, 2021 · Primary completion Jan 31, 2024
Drug: CABENUVA · For: HIV Infections
Sites: Evans, Georgia; East Lansing, Michigan; Novi, Michigan · 15 sites in all
Janssen Scientific Affairs, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04442737 · 103 participants · Start Jul 1, 2020 · Primary completion Aug 7, 2023
Drug: D/C/F/TAF FDC; TAF/FTC FDC and 1 more · For: HIV-1
Sites: Birmingham, Alabama; Bakersfield, California; Beverly Hills, California · 34 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05648357 · 250 participants · Start Dec 14, 2023 · Primary completion Feb 26, 2024
Drug: Fluarix Tetra Vaccine · For: Influenza, Human
Sites: Belagavi, India; Kattankulathur, India; Nashik, India · 6 sites in all
- Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With EntecavirPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT06000657 · 196 participants · Start Aug 28, 2023 · Primary completion Feb 3, 2025
Drug: Vemliver tablet; Baracross Tablet · For: Hepatitis B, Chronic
Sites: Seoul, South Korea
Boehringer IngelheimBoehringer Ingelheim
NCT00144261 · 15 participants · Start Nov 1, 2003 · Primary completion Dec 1, 2006
Drug: nevirapine · For: HIV Infections; Metabolism, Lipids
Sites: Amsterdam, Netherlands; London, United Kingdom · 3 sites in all
Astellas Pharma Europe Ltd.Astellas (ALPMY)
NCT02437591 · 25 participants · Start Aug 13, 2015 · Primary completion May 12, 2016
Drug: fidaxomicin · For: Inflammatory Bowel Disease (IBD); Clostridium Difficile Infection (CDI)
Sites: Graz, Austria; Clichy, France; Paris, France · 12 sites in all
- Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B PatientsPivotal-lookingCompleted
Dong-A ST Co., Ltd.Industry
NCT05957380 · 120 participants · Start Mar 20, 2023 · Primary completion Sep 30, 2024
Drug: DA-2803; DA-2803-R and 2 more · For: Hepatitis B
Sites: Seoul, South Korea
PfizerPfizer (PFE)
NCT04882085 · 60 participants · Start Aug 26, 2021 · Primary completion Aug 31, 2023
Drug: Zavicefta, Ceftazidime-Avibactam; Best Available Treatment · For: Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia and 3 more
Sites: Bengbu, China; Chizhou, China; Fuyang, China · 37 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.